CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 6 (2025) Vis Cancer Med, 6 (2025) 1 References
Open Access
Issue
Vis Cancer Med
Volume 6, 2025
Article Number 1
Number of page(s) 6
DOI https://doi.org/10.1051/vcm/2025003
Published online 22 January 2025
  1. Yan T, Yu L, Zhang J, Chen Y, Fu Y, Tang J, et al. Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events. Front Immunol. 2024;15:1292122. [CrossRef] [Google Scholar]
  2. Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers. 2021;13(20):5218. [CrossRef] [PubMed] [Google Scholar]
  3. Mahalingam P, Newsom-Davis T. Cancer immunotherapy and the management of side effects. Clin Med Lond Engl. 2023; 23(1):56–60. [CrossRef] [Google Scholar]
  4. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. [CrossRef] [PubMed] [Google Scholar]
  5. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739–1747. [CrossRef] [PubMed] [Google Scholar]
  6. Sharma A, Alexander G, Chu JH, Markopoulos A, Maloul G, Ayub MT, et al. Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials. J Am Heart Assoc. 2024;13(10):e032620. [CrossRef] [PubMed] [Google Scholar]
  7. Johnson MT, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. [CrossRef] [PubMed] [Google Scholar]
  8. Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-cell antineoplastic therapies. JACC CardioOncol. 2022;4(5):616–623. [CrossRef] [PubMed] [Google Scholar]
  9. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. [CrossRef] [PubMed] [Google Scholar]
  10. Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, et al. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. J Immunother Cancer. 2021;9(2):e001701. [CrossRef] [PubMed] [Google Scholar]
  11. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411–422. [CrossRef] [PubMed] [Google Scholar]
  12. Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632–644. [CrossRef] [PubMed] [Google Scholar]
  13. Khattak A, Weber JS, Meniawy T, Taylor MH, Ansstas G, Kim KB, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157–P201/KEYNOTE-942 trial. J Clin Oncol. 2023;41(17_suppl):LBA9503. [CrossRef] [Google Scholar]
  14. Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, et al. Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology. 2018;7(6):e1433516. [CrossRef] [PubMed] [Google Scholar]
  15. Lamm DL. Bacillus calmette-guerin immunotherapy for bladder cancer. J Urol. 1985;134(1):40–46. [CrossRef] [PubMed] [Google Scholar]
  16. Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K. Cardiotoxicity associated with anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) therapy: recognition, risk factors, and management. Dis Basel Switz. 2021;9(1):20. [Google Scholar]
  17. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS. Cardiovascular toxicities of immune checkpoint inhibitors. J Am Coll Cardiol. 2019;74(13):1714–1727. [CrossRef] [PubMed] [Google Scholar]
  18. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461–1475. [CrossRef] [PubMed] [Google Scholar]
  19. Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420. [Google Scholar]
  20. Antiarrhythmic Drugs. Types, use & side effects – Heart Foundation NZ [Internet] [cited 2024 Sep 17]. Available from: https://www.heartfoundation.org.nz/your-heart/heart-treatments/medications/anti-arrhythmics. [Google Scholar]
  21. Slivnick JA, Betz J, Kalbfleisch S, Crouser ED, Kahwash R. High-dose intravenous glucocorticoids are effective in the acute management of ventricular arrhythmias in cardiac sarcoidosis: A case series. Hear Case Rep. 2020;6(10):706–710. [Google Scholar]
  22. Mayo Clinic [Internet]. [cited 2024 Sep 17]. Dilated cardiomyopathy: Enlarged heart struggles to pump blood-Dilated cardiomyopathy – Diagnosis & treatment. Available from: https://www.mayoclinic.org/diseases-conditions/dilated-cardiomyopathy/diagnosis-treatment/drc-20353155. [Google Scholar]
  23. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–1020. [CrossRef] [PubMed] [Google Scholar]
  24. Raschi E, Rossi S, De Giglio A, Fusaroli M, Burgazzi F, Rinaldi R, et al. Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians. Drug Saf. 2023;46(9):819–833. [CrossRef] [PubMed] [Google Scholar]
  25. Myocarditis in patients treated with immune checkpoint inhibitors – clinical key [Internet]. [cited 2024 Sep 17]. Available from: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0735109718333680?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0735109718333680%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F. [Google Scholar]
  26. Matzen E, Bartels LE, Løgstrup B, Horskær S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncol. 2021;7:27. [CrossRef] [Google Scholar]
  27. Cooper LT. Myocarditis. N Engl J Med. 360(15):1526–1538. [Google Scholar]
  28. Zhou YW, Zhu YJ, Wang MN, Xie Y, Chen CY, Zhang T, et al. Immune checkpoint inhibitor- associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol. 2019;10:1350. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01350/full. [CrossRef] [PubMed] [Google Scholar]
  29. Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, et al. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med. 2023;10:1090103. [Internet]. Available from: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1090103/full. [CrossRef] [PubMed] [Google Scholar]
  30. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229–4361. [CrossRef] [PubMed] [Google Scholar]
  31. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. [CrossRef] [PubMed] [Google Scholar]
  32. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–2311. [CrossRef] [PubMed] [Google Scholar]
  33. Wang F, Sun X, Qin S, Hua H, Liu X, Yang L, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. Chin Clin Oncol. 2020; 9(2):16. [CrossRef] [PubMed] [Google Scholar]
  34. Young MN, Kolte D, Cadigan ME, Laikhter E, Sinclair K, Pomerantsev E, et al. Multidisciplinary heart team approach for complex coronary artery disease: single center clinical presentation. J Am Heart Assoc. 2020;9(8):e014738. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.